Pet Pharm Biotech Co (ROCO:7762) Notes Receivable: NT$0.0 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:7762 Pet Pharm Biotech Co Ltd ROCO:7762
19 GF Score
Price NT$49.85
! 5 Warning Signs
View Full Analysis

What is Pet Pharm Biotech Co Notes Receivable?

Pet Pharm Biotech Co ROCO:7762 +0.20% 19 Notes Receivable is NT$0.0 Mil as of Dec. 2025. GuruFocus rates ROCO:7762 with a GF Score™ of 19/100. The stock has 5 warning signs investors should review.

Pet Pharm Biotech Co's Notes Receivable for the quarter that ended in Dec. 2025 was NT$0.0 Mil.

Pet Pharm Biotech Co Notes Receivable Related Terms

Pet Pharm Biotech Co Notes Receivable Historical Data

* Premium members only.

The historical data trend for Pet Pharm Biotech Co's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pet Pharm Biotech Co Notes Receivable Chart

Pet Pharm Biotech Co Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Notes Receivable
0.00 0.00 0.00 0.00

Pet Pharm Biotech Co Semi-Annual Data
Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Notes Receivable Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00
ROCO:7762
19GF Score
Pet Pharm Biotech Co Ltd ROCO:7762
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pet Pharm Biotech Co Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of NT$0.0 Mil mean?
Pet Pharm Biotech Co (ROCO:7762) has a Notes Receivable of NT$0.0 Mil as of Dec. 2025. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Pet Pharm Biotech Co and its competitors.
Is Pet Pharm Biotech Co's Notes Receivable too high?
Pet Pharm Biotech Co's current Notes Receivable is NT$0.0 Mil. Overall, Pet Pharm Biotech Co has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Pet Pharm Biotech Co's Notes Receivable compare to LLY and JNJ?
Pet Pharm Biotech Co's Notes Receivable of NT$0.0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Drug Manufacturers company?
A good Notes Receivable depends on the Drug Manufacturers industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Pet Pharm Biotech Co and its competitors. Pet Pharm Biotech Co's current Notes Receivable is NT$0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pet Pharm Biotech Co stock overvalued right now?
Pet Pharm Biotech Co (ROCO:7762) has a current Notes Receivable of NT$0.0 Mil. The current Notes Receivable is NT$0.0 Mil. Pet Pharm Biotech Co's overall GF Score™ is 19/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Pet Pharm Biotech Co (ROCO:7762), the current Notes Receivable is NT$0.0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Pet Pharm Biotech Co Business Description

Address 143, Hougang 1st Road, 1-2F., No. 141, Xinzhuang District, New Taipei City, TWN, 242051
Pet Pharm Biotech Co Ltd is a Pharmaceutical company. The company is engaged in manufacturing medicinal products and medicine drugs. The products offered by the company include FDG Fluodeoxyglucose Injection (18F-FDG), Naolixi Injection (18F-FBB), Sodium fluoride injection (18F-NaF), and others.
19GF Score

Get the complete analysis for ROCO:7762

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$49.85
Price